



Onyx Pharmaceuticals, Inc.  
3031 Research Dr.  
Richmond, CA 94806  
[www.onyx-pharm.com](http://www.onyx-pharm.com)  
Tel. 510.222.9700  
Fax 510.222.9758

RECEIVED  
CENTRAL FAX CENTER

JAN 26 2004

OFFICIAL

Facsimile Transmittal Form

TO: Ex. Sheridan Swope

FROM: leg. ltrg

DATE: 1/26/04

Number of Pages (including cover): 3

Comments:

Response to restriction  
requirement  
(09/974, 573)

WARNING: This facsimile message and accompanying documents are intended only for the use of the addressee indicated above. Information that is privileged or otherwise confidential may be contained therein. If you are not the intended recipient, you are hereby notified that any dissemination, copying, review or use of this message, documents or information contained therein is strictly prohibited. If you have received this message in error, please notify us immediately by telephone or facsimile and mail the original to us at the above address. Thank you.


## CERTIFICATE OF FACSIMILE TRANSMITTAL

Facsimile Number (703) 308-4242

Date of Transmission

1/26/04

I hereby certify that this correspondence (and all other documents mentioned therein) is being transmitted by facsimile to the Mail Stop Non-Fee Amendment, Commissioner for Patents P.O. Box 145, Alexandria, VA 22313-1450, to the above facsimile number on the above-date



Docket: ONYX1048-ORD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application: Roger Williams et al.

SC/Serial No: 09/974,573

Filed: October 9, 2001

Title: Phosphoinositide 3-Kinases

RESPONSE TO OFFICE ACTION UNDER 35 U.S.C. §121

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Responsive to the Office Action mailed September 26, 2003, setting forth a Restriction Requirement, Applicants elect without traverse, group 1, claim 1. This group was not listed by the Examiner as requiring an election of species.


Accompany this Response is a Petition for 3 -month Extension of Time.

The Commissioner is authorized to charge any fees associated with this communication to Deposit Account No. 15-0615 for any matter in connection with this response, including any fee for extension of time, which may be required.

Respectfully submitted,

Date: 1/26/04

By:

  
Gregory Giotta  
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.  
3031 Research Drive  
Richmond, California 94806  
Telephone (510) 222-9700  
Facsimile (510) 222-09758

RECEIVED  
CENTRAL FAX CENTER

JAN 26 2004

OFFICIAL